Chemistry:4'-Fluorocannabidiol
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H29FO2 |
| Molar mass | 332.459 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4'-Fluorocannabidiol (also known as PECS-101 and 4'-F-CBD, and formerly as HUF-101 and HU-474[1]) is a fluorinated cannabidiol derivative that has more potent anxiolytic, antidepressant, antipsychotic and anti-compulsive activity in mice compared to its parent compound.[2][3][4][5] It was first synthesized in 2016, alongside 10-fluorocannabidiol diacetate and 8,9-dihydro-7-fluorocannabidiol, which showed much weaker activity.[2]
Synthesis
4'-Fluorocannabidiol has been synthesized from isolated cannabidiol by putting it in dry dichloromethane and adding 1-fluoropyridinium triflate.[2]
See also
- 7-Hydroxycannabidiol
- 8,9-Dihydrocannabidiol
- Abnormal cannabidiol
- Cannabinoids
- Cannabinoid receptors
- HU-331
- KLS-13019
- O-1602
- O-1918
References
- ↑ "Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101". Molecules 26 (17): 5354. 2 September 2021. doi:10.3390/molecules26175354. PMID 34500787.
- ↑ 2.0 2.1 2.2 "Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects". PLOS ONE 11 (7): e0158779. 14 July 2016. doi:10.1371/journal.pone.0158779. PMID 27416026. Bibcode: 2016PLoSO..1158779B.
- ↑ "An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol". Frontiers in Pharmacology 8: 422. 2017. doi:10.3389/fphar.2017.00422. PMID 28701957.
- ↑ "Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative". Progress in Neuro-Psychopharmacology & Biological Psychiatry 79 (Pt B): 369–377. October 2017. doi:10.1016/j.pnpbp.2017.07.012. PMID 28720466.
- ↑ "Neuronal preservation and reactive gliosis attenuation following neonatal sciatic nerve axotomy by a fluorinated cannabidiol derivative". Neuropharmacology 140: 201–208. September 2018. doi:10.1016/j.neuropharm.2018.08.009. PMID 30096328.
 |  |
